Cobalamin‐Related Remethylation Disorders: Pregnancy Outcomes and Prenatal Treatment‐New Cases and a Literature Study
Journal of Inherited Metabolic Disease · 2026
DOI: 10.1002/jimd.70243 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Inherited Metabolic Disease, 2026. Verfasst von Karolina M Stepien und 22 weiteren Autor:innen. Beteiligte Einrichtung: Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK. Hauptthemen laut MEDLINE: Vitamin B 12 Deficiency, Vitamin B 12, Homocystinuria, Amino Acid Metabolism, Inborn Errors. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, Intramural NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Cobalamin‐related remethylation disorders (cbl‐RD) are rare, heterogenous conditions with a wide phenotypic spectrum, including prenatal and early infantile manifestations. Data on pregnancy outcomes in affected women and the efficacy and safety of prenatal treatment of affected fetuses remain limited. Here we report (1) five women with cbl‐RDs (3 cblC/epi‐cblC, 1 cblD, 1 cblE) who had in total nine pregnancies and (2) eight fetuses with cbl‐RD (7 cblC, 1 cblF) diagnosed and treated prenatally. All affected mothers were treated with hydroxocobalamin (OHCbl) during pregnancy and two also received betaine and carnitine. Complications included three preterm deliveries and nephrotic‐range proteinuria in one previously undiagnosed mother with cblE. All offspring had favourable outcomes. In pregnancies with affected fetuses, OHCbl was administered to the mother between gestational weeks 5 and 32 at varying doses. Prenatally treated cblC cases exhibited attenuated phenotypes without microcephaly, epilepsy, or severe multisystemic disease. Notably, three of five infants harbouring severe MMACHC variants, who received high‐dose pre‐ and postnatal OHCbl, exhibited normal neurodevelopment and no maculopathy up to age 2–3 years, though variability in genotype, treatment regimens, and duration of follow‐up limit generalizability. A literature review identified nine additional pregnancies in women with cbl‐RD and seven prenatally treated fetuses, with follow‐up available for three. Collectively, our main findings support the safety of maternal and fetal OHCbl treatment during pregnancy. We recommend that when combined with preconception counselling, early standardized diagnosis, optimal monitoring and postnatal care, prenatal OHCbl therapy can improve pregnancy outcomes and mitigate neurodevelopmental and ophthalmic complications in cbl‐RD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK.
- Department of Inborn Errors of Metabolism and Pediatrics, Institute of Mother and Child, Warsaw, Poland.
- National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Centre de référence maladies héréditaires du métabolisme, Hôpital Timone Enfants, APHM, Marseille, France.
- Neurometabolic Unit, Children's Institute, São Paulo, Brazil.
- Division of Genetic Medicine, Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, Washington, USA.
ORCID-Profile: Karolina M Stepien, Jolanta Sykut-Cegielska, Jennifer Sloan, Flavia Piazzon, Sarah Bick, Edwin C Ferren, Nina Gold, Apolline Imbard, Mirian C H Janssen, Pavel Jesina, Lisa A Joseph, Amanda Krzywdzińska-Rogowska, Fanny Mochel, Manuel Schiff, Ida Vanessa Schwartz, Audrey Thurm, Wadih M Zein, Charles P Venditti, Martina Huemer, Irini Manoli
Förderung
- NIH HHS
- Intramural NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Stepien, K. M., Sykut-Cegielska, J., Sloan, J., Piazzon, F., Bick, S., Bouchereau, J., Ferren, E. C., Gold, N., Imbard, A., Janssen, M. C. H., Jesina, P., Joseph, L. A., Krzywdzińska-Rogowska, A., Lapagesse, L., Mochel, F., Ryzin, C. V., Schiff, M., Schwartz, I. V., Thurm, A., …, & Manoli, I. (2026). Cobalamin‐Related Remethylation Disorders: Pregnancy Outcomes and Prenatal Treatment‐New Cases and a Literature Study. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70243
Vancouver
Stepien KM, Sykut-Cegielska J, Sloan J, Piazzon F, Bick S, Bouchereau J, et al. Cobalamin‐Related Remethylation Disorders: Pregnancy Outcomes and Prenatal Treatment‐New Cases and a Literature Study. Journal of Inherited Metabolic Disease. 2026. doi:10.1002/jimd.70243
BibTeX
@article{Stepien2026,
author = {Stepien, Karolina M and Sykut-Cegielska, Jolanta and Sloan, Jennifer and Piazzon, Flavia and Bick, Sarah and Bouchereau, Juliette and Ferren, Edwin C and Gold, Nina and Imbard, Apolline and Janssen, Mirian C H and Jesina, Pavel and Joseph, Lisa A and Krzywdzińska-Rogowska, Amanda and Lapagesse, Louise and Mochel, Fanny and Ryzin, Carol Van and Schiff, Manuel and Schwartz, Ida Vanessa and Thurm, Audrey and Zein, Wadih M and Venditti, Charles P and Huemer, Martina and Manoli, Irini},
title = {Cobalamin‐Related Remethylation Disorders: Pregnancy Outcomes and Prenatal Treatment‐New Cases and a Literature Study},
journal = {Journal of Inherited Metabolic Disease},
year = {2026},
doi = {10.1002/jimd.70243}
}
EUVIMED